AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Trivolib 2mg/500mg/0.2mg Tablet ER

Prescription Icon
Prescription Required

Marketer

Akums Drugs & Pharmaceuticals Ltd

Salt Composition

Glimepiride (2mg) + Metformin (500mg) + Voglibose (0.2mg)

Overview Trivolib 2mg/500mg/0.2mg Tablet ER

Diabetol-XR 2mg/500mg/0.2mg extended-release tablets are classified as antidiabetic agents. This combination medication manages type 2 diabetes in adults by regulating blood glucose. Diabetol-XR should be ingested with food, consistently at the same time daily for optimal efficacy. Dosage is determined by your physician and may be adjusted based on blood sugar monitoring. Continued use is crucial, even with controlled blood sugar, as abrupt cessation can elevate glucose levels, increasing the risk of kidney complications, vision impairment, neuropathy, and limb loss. This medication complements a comprehensive diabetes management plan including diet, exercise, and weight management as directed by your doctor. Lifestyle choices significantly influence diabetes control. Hypoglycemia (low blood sugar) is the most frequent adverse effect, characterized by sweating, dizziness, headache, and tremors. Regular meals and readily available glucose sources (e.g., sugary snacks, juice) are essential. Alcohol consumption should be limited due to its hypoglycemic potential. Additional potential side effects include altered taste, nausea, diarrhea, abdominal discomfort, headache, edema, blurred vision, fractures, and upper respiratory infections. Weight gain is also possible. Diabetol-XR is contraindicated in type 1 diabetes, diabetic ketoacidosis, and severe hepatic or renal impairment. Individuals with a history of heart disease should inform their physician before commencing treatment. Pregnant or lactating women require medical consultation prior to use. Regular blood glucose monitoring and periodic blood tests (complete blood count and liver function tests) are recommended.

Uses of Trivolib 2mg/500mg/0.2mg Tablet ER

Managing Type 2 Diabetes

Major Benefits of Trivolib 2mg/500mg/0.2mg Tablet ER:

Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Ingest the Trivolib 2mg/500mg/0.2mg Extended-Release tablet whole; do not chew, crush, or divide it. Administer this medication on an empty stomach.

Common Side effects of Trivolib 2mg/500mg/0.2mg Tablet ER:

  • Nausea
  • Diarrhea
  • Abdominal pain
  • Hypoglycemia (low blood glucose level)
  • Loss of appetite

How to use Trivolib 2mg/500mg/0.2mg Tablet ER:

Follow your doctor's instructions precisely regarding dosage and treatment length for Trivolib 2mg/500mg/0.2mg Extended-Release Tablets. Ingest the tablets whole; avoid chewing, crushing, or breaking them. Administer on an empty stomach.

How Trivolib 2mg/500mg/0.2mg Tablet ER works:

Extended-release Trivolib tablets (2mg/500mg/0.2mg) contain a triple-drug formulation for diabetes management.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Concurrent alcohol use with Trivolib 2mg/500mg/0.2mg Extended-Release tablets is inadvisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

Extended-release Trivolib tablets (2mg/500mg/0.2mg) may pose pregnancy risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against potential hazards prior to prescribing. Physician consultation is recommended.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Trivolib tablets (2mg/500mg/0.2mg) are likely unsafe for breastfeeding mothers. Available human data indicates potential transfer to breast milk, posing a risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyUNSAFE

Extended-release Trivolib tablets (2mg/500mg/0.2mg) are likely unsafe for individuals with kidney impairment and should be omitted. Medical advice is recommended. Moreover, this medication is contraindicated in patients exhibiting severe kidney dysfunction.

LiverLiverCAUTION

Patients with liver impairment should use Trivolib 2mg/500mg/0.2mg Extended-Release Tablets cautiously. Dose modification may be necessary for those with liver disease. Physician consultation is advised. A low initial dose of Trivolib 2mg/500mg/0.2mg Extended-Release Tablets is typically recommended for individuals with mild to moderate hepatic dysfunction; however, its use is contraindicated in cases of severe liver disease.

What if you forget to take Trivolib 2mg/500mg/0.2mg Tablet ER :

Should you forget a Trivolib 2mg/500mg/0.2mg Extended-Release Tablet, ingest it immediately upon remembrance. However, if your next scheduled dose is imminent, omit the missed tablet and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Trivolib 2mg/500mg/0.2mg Tablet ER

LabelValue
Addictive None.
Medication Classification Diabetes medication

FAQs on Trivolib 2mg/500mg/0.2mg Tablet ER

Trivolib 2mg/500mg/0.2mg Extended-Release tablets contain glimepiride, metformin, and voglibose. This triple-drug therapy manages type 2 diabetes mellitus in adults, enhancing glycemic control when combined with a healthy diet and exercise regimen. Glimepiride stimulates pancreatic insulin secretion, reducing blood glucose. Metformin decreases hepatic glucose production and improves insulin responsiveness. Voglibose, an alpha-glucosidase inhibitor, reduces post-meal blood sugar. This formulation is unsuitable for treating type 1 diabetes.
Taking Trivolib 2mg/500mg/0.2mg Extended-Release tablets may result in frequently reported adverse events including low blood sugar, queasiness, loose stools, changes in taste perception, gas, abdominal discomfort, cephalalgia, dermatitis, and upper respiratory illness.
Patients with hypersensitivity to Trivolib 2mg/500mg/0.2mg Tablet ER constituents or inactive ingredients should not receive this medication. Its administration is contraindicated in individuals with moderate to severe renal impairment, inflammatory bowel conditions, colonic ulcers, and underlying metabolic acidosis, such as diabetic ketoacidosis.
Combining Trivolib 2mg/500mg/0.2mg extended-release tablets and alcohol is unsafe. This combination can reduce blood glucose, potentially causing hypoglycemia, and heighten the risk of lactic acidosis.
Indeed, Trivolib 2mg/500mg/0.2mg Extended-Release Tablets can lead to low blood sugar (hypoglycemia). Low blood sugar may manifest as nausea, headache, irritability, hunger, sweating, lightheadedness, rapid heartbeat, and feelings of anxiety or tremor. This risk increases with skipped or delayed meals, alcohol consumption, excessive physical activity, or concurrent use of other diabetes medications. Consequently, consistent blood glucose monitoring is crucial. Carrying readily available glucose sources, such as glucose tablets, honey, or fruit juice, is recommended.
Retain this medication within its original, sealed packaging. Follow the storage guidelines printed on the package or label. Discard any leftover medication. Prevent access by children, pets, and others.
Trivolib 2mg/500mg/0.2mg ...
268
MRP 327
18% off